MicroRNA-92a as a marker of treatment response and survival in adult acute myeloid leukemia patients

References

• Watts J, Nimer S. Recent advances in the understanding and treatment of acute myeloid leukemia. F1000Res. 2018;7:1196.
   Google Scholar
• Khaled SA, Nabih O, Abdel Aziz NM, et al. Myeloid leukemias: a glance at Middle Eastern Centers. J Blood Med. 2019;10:425–433.
   PubMed Web of Science ®Google Scholar
• Luppi M, Fabbiano F, Visani G, et al. Novel agents for acute myeloid leukemia. Cancers (Basel). 2018;10(11):429.
   PubMed Web of Science ®Google Scholar
• Beyar-Katz O, Gill S. Novel approaches to acute myeloid leukemia immunotherapy. Clin Cancer Res. 2018;24(22):5502–5515.
   PubMed Web of Science ®Google Scholar
• Butz H, Patocs A. MicroRNAs in endocrine tumors. EJIFCC. 2019;30(2):146–164.
   PubMedGoogle Scholar
• Khan AQ, Ahmed EI, Elareer NR, et al. Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells. 2019;8(8):840.
   PubMed Web of Science ®Google Scholar
• Cui M, Wang H, Yao X, et al. Circulating MicroRNAs in cancer: potential and challenge. Front Genet. 2019;10:626.
   PubMed Web of Science ®Google Scholar
• Orso F, Quirico L, Dettori D, et al. Role of miRNAs in tumor and endothelial cell interactions during tumor progression. Semin Cancer Biol. 2019;60:214–224.
   PubMed Web of Science ®Google Scholar
• Mardani R, Jafari Najaf Abadi MH, Motieian M, et al. MicroRNA in leukemia: tumor suppressors and oncogenes with prognostic potential. J Cell Physiol. 2019;234(6):8465–8486.
   PubMed Web of Science ®Google Scholar
• Zhang H, Cao H, Xu D, et al. MicroRNA-92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway. OncoTargets Ther. 2016;9:3579–3588.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zuo J, Tan Q, et al. Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark. 2017;18(3):319–327.
   PubMed Web of Science ®Google Scholar
• Su Z, Yang H, Zhao M, et al. MicroRNA-92a promotes cell proliferation in cervical cancer via inhibiting p21 expression and promoting cell cycle progression. Oncol Res. 2017;25(1):137–145.
   PubMed Web of Science ®Google Scholar
• Torres A, Kozak J, Korolczuk A, et al. In vitro and in vivo activity of miR-92a-locked nucleic acid (LNA)-inhibitor against endometrial cancer. BMC Cancer. 2016;16(1):822.
   PubMed Web of Science ®Google Scholar
• Liu PJ, Ye YX, Wang YX, et al. MiRNA-92a promotes cell proliferation and invasion through binding to KLF4 in glioma. Eur Rev Med Pharmacol Sci. 2019;23(15):6612–6620.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One. 2009;4(5):e5532.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 2010;3:347.
   PubMedGoogle Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032.
   PubMed Web of Science ®Google Scholar
• Elhamamsy AR, El Sharkawy MS, Zanaty AF, et al. Circulating miR-92a, miR-143 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. Int J Mol Cell Med. 2017;6(2):77–86.
   PubMed Web of Science ®Google Scholar
• Gado MM, Mousa NO, Badawy MA, et al. Assessment of the diagnostic potential of miR-29a-3p and miR-92a-3p as circulatory biomarkers in acute myeloid leukemia. Asian Pac J Cancer Prev. 2019;20(12):3625–3633.
   PubMedGoogle Scholar
• Umezu T, Ohyashiki K, Kuroda M, et al. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013;32(22):2747–2755.
   PubMed Web of Science ®Google Scholar
• Sharifi M, Salehi R, Gheisari Y, et al. Inhibition of microRNA miR-92a induces apoptosis and necrosis in human acute promyelocytic leukemia. Adv Biomed Res. 2014;3:61.
   PubMedGoogle Scholar
• Gu Y, Si J, Xiao X, et al. miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) expression in acute myeloid leukemia. Oncol Res. 2017;25(7):1069–1079.
   PubMed Web of Science ®Google Scholar
• Cui J, Li Q, Luo M, et al. Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. Oncoimmunology. 2018;7(7):e1448330.
   PubMed Web of Science ®Google Scholar
• He C, Luo B, Jiang N, et al. OncomiR or antioncomiR: role of miRNAs in acute myeloid leukemia. Leuk Lymphoma. 2019;60(2):284–294.
   PubMed Web of Science ®Google Scholar
• Liu G-H, Zhou Z-G, Chen R, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biol. 2013;34(4):2175–2181.
   PubMedGoogle Scholar
• Peng Q, Shen Y, Lin K, et al. Identification of microRNA-92a and the related combination biomarkers as promising substrates in predicting risk, recurrence and poor survival of colorectal cancer. J Cancer. 2019;10(14):3154–3171.
   PubMed Web of Science ®Google Scholar
• Ren C, Wang W, Han C, et al. Expression and prognostic value of miR-92a in patients with gastric cancer. Tumor Biol. 2016;37(7):9483–9491.
   PubMedGoogle Scholar
• Jiang X, Li X, Wu F, et al. Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7. Gene. 2017;606:10–16.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhu S, Tao Z, et al. High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer. Cancer Med. 2018;7(1):21–31.
   PubMed Web of Science ®Google Scholar
• Xu P, Xia T, Ling Y, et al. MiRNAs with prognostic significance in multiple myeloma: a systemic review and meta-analysis. Medicine (Baltimore). 2019;98(33):e16711.
   PubMed Web of Science ®Google Scholar
• Conte M, Dell'Aversana C, Sgueglia G, et al. HDAC2-dependent miRNA signature in acute myeloid leukemia. FEBS Lett. 2019;593(18):2574–2584.
   PubMed Web of Science ®Google Scholar